Free Trial
→ Why I'm selling my Snapback Indicator for just $7 (From Base Camp Trading) (Ad)tc pixel
OTCMKTS:NWBO

Northwest Biotherapeutics 11/12/2024 Earnings Results & Report

Northwest Biotherapeutics logo
$0.17 +0.00 (+0.96%)
As of 11/11/2026 03:55 PM Eastern

Northwest Biotherapeutics reported earnings on November 12, 2024. The company reported EPS of -$0.02, while revenue was $360 thousand.

Research:ProfileEarnings History

Earnings Announcement Details

Report Date
Time
After Market Closes

Northwest Biotherapeutics EPS Results

Actual EPS
-$0.02
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Northwest Biotherapeutics Revenue Results

Actual Revenue
$360 thousand
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Upcoming Earnings

Northwest Biotherapeutics' next earnings date is estimated for Thursday, November 12, 2026, based on past reporting schedules.

Conference Call Resources

Northwest Biotherapeutics Earnings FAQ

Northwest Biotherapeutics (OTCMKTS:NWBO) reported earnings of -$0.02 per share for the quarter. The report was announced on Tuesday, November 12, 2024.

Northwest Biotherapeutics reported revenue of $360 thousand for the quarter.

Northwest Biotherapeutics' next earnings date is estimated for Thursday, November 12, 2026. MarketBeat tracks confirmed and estimated earnings dates for Northwest Biotherapeutics on the company's earnings history page.

Northwest Biotherapeutics Earnings Headlines

Northwest Biotherapeutics Announces Expansion of Its Technical Team
October 26, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/northwest-biotherapeutics-announces-expansion-of-its-technical-team-302919492.html
Northwest Biotherapeutics announces NHSBT collaboration to support DCVax-L production in the UK
October 9, 2026  |  msn.comhttps://www.msn.com/en-us/money/general/northwest-biotherapeutics-announces-nhsbt-collaboration-to-support-dcvax-l-production-in-the-uk/ar-AA2dTtn4
A free stock pick, from me to you
Elon's paid this chip supplier since 2012. When NVIDIA tried to buy the company, he fought the deal. Without its chip, his AI satellites don't fly. Now he wants 1,000,000 of them in orbit, 100 times what's up there today, and every one pays this company a royalty. Dylan believes shares could react by December 8th.tc pixel
 |  Behind the Markets (Ad)
Northwest Biotherapeutics and the UK National Health Service Blood and Transplant Announce Collaboration to Support DCVax®-L Production
October 8, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/northwest-biotherapeutics-and-the-uk-national-health-service-blood-and-transplant-announce-collaboration-to-support-dcvax-l-production-302903002.html
Northwest Biotherapeutics highlights personalized cancer vaccine approach at NHS oncology conference
October 6, 2026  |  msn.comhttps://www.msn.com/en-us/money/general/northwest-biotherapeutics-highlights-personalized-cancer-vaccine-approach-at-nhs-oncology-conference/ar-AA2dGVTW
Northwest Biotherapeutics Announces Keynote Presentation on Harnessing Immunity: A Personalized, Multi-Target Approach to Cancer At the UK National Health Service Annual ...
October 6, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/northwest-biotherapeutics-announces-keynote-presentation-070000164.html
See More Northwest Biotherapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Northwest Biotherapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Northwest Biotherapeutics and other key companies, straight to your email.

About Northwest Biotherapeutics

Northwest Biotherapeutics (OTCMKTS:NWBO) is a biotechnology company developing immunotherapies for cancer, with a focus on treatments made from a patient’s own immune cells. Its platform uses dendritic cells, which can help the immune system recognize and respond to cancer.

The company’s lead product candidate, DCVax-L, is a personalized dendritic-cell therapy being developed for glioblastoma, an aggressive form of brain cancer. Northwest Biotherapeutics has also developed DCVax-Direct, an investigational therapy designed to be injected into tumors. These candidates are not established treatments, and their development is subject to clinical and regulatory review.

Northwest Biotherapeutics is headquartered in the United States and has manufacturing operations in the United Kingdom. Its work has included clinical research in multiple countries.

View Northwest Biotherapeutics Profile
Earnings Tools